Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225].

Astrid K Gnekow,David A Walker,Daniela Kandels,Susan Picton,Giorgio Perilongo,Jacques Grill,Tore Stokland,Per Eric Sandstrom,Monika Warmuth-Metz,Torsten Pietsch,Felice Giangaspero,René Schmidt,Andreas Faldum,Denise Kilmartin,Angela De Paoli,Gian Luca De Salvo

European Journal of Cancer（2018）

引用 3|浏览40

暂无评分

摘要

Corrigendum to “A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report” [Eur J of Canc (2017) 206–225]

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Corrigendum to &quot;A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report&quot; [Eur J of Canc (2017) 206-225].

Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225].